Royalty Report: Diagnostic, Drugs, Cancer – Collection: 773

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Diagnostic
  • Drugs
  • Cancer
  • Disease
  • Biotechnology
  • Diagnostic Substances
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 773

License Grant
German Laboratory, government organization, grants to Licensee of Singapore an exclusive, worldwide license, including the right to sublicense, to make, have made, use, sell, have sold, import, have imported, and otherwise to use or practice Licensor Intellectual Property in the Field.
License Property
Licensed Material shall mean Histone macroH2A isoform antibodies and related material provided to Licensee pursuant to this Agreement and/or any and all antibodies, antibody fragments and antibody preparations and related material (like e.g. hybridoma cell lines) provided by Licensor to the Licensee in the Field after the date of this Agreement.

Licensor Invention record nº 554 and any developments, ideas, know-how, trade secrets, data information of the Licensor in the field of tumor markers, and/or the related intellectual property rights in any of the foregoing including without limitation patent applications and patent applications made of a part thereof, already existing before the Effective Date, any patents based thereon, any divisional, continuations, continuations-in-part, reexaminations or reissues thereof as well as certificates of addition and utility models, and any and all patents granted thereon, including the patent application No. EP 09 008 679.4 entitled Diagnostic method for predicting the risk of cancer recurrence based on Histone macro H2A isoforms.

Field of Use
Field shall mean the field of cancer diagnosis and cancer prognosis.

IPSCIO Record ID: 5926

License Grant
The Licensor hereby grants to Licensee a royalty-bearing, exclusive license under licensed subject matter to manufacture, have manufactured, use, import, offer to sell and/or sell Licensed Products within Licensed Territory for use within Licensed Field.

Licensee entered into a License and Technology Licensing Agreement with a University's Cancer Center to commercialize technology developed for cancer detection in animals and humans based on a tumor marker known as p65 which has been demonstrated to show elevated levels in the blood of canine and human cancer patients.

License Property
MDA89-015, which consists of the following three patents: 'Tumor Marker Protein and Antibodies Thereto for Cancer Risk Assessment or Diag- nosis,' U.S. Patent No. 5,310,653, Issued May 10, 1994, Inventors: Margaret Hanausek-Walaszek; Thomas J. Slaga; Zbigniew Walaszek.

'Diagnostic and Premonitoring Uses of a 65 kDa Tumor-Associated Protein in Com- panion and Domestic Animal Malignancy,' U.S. Patent No. 5,411,868, Issued May 2, 1995; Inventors: Margaret Hanausek-Waluszek; Lezlee Coghlan.

'Tumor Marker Protein for Cancer Risk Assessment,: U.S, Patent No. 5,773,215, Issued June 30, 1998, Inventors: Margaret Hanausek-Walaszek; Thomas J. Slap; and Zbigniew Walaszek.

IPSCIO Record ID: 203487

License Grant
Licensor hereby grants to Licensee a worldwide exclusive right and license under the Licensor Patent Rights, the Licensor Know-How, and Licensors rights in the Joint Patent Rights and the Joint Know-How, to make, have made, use, have used, sell, distribute, offer for sale and import Licensed Products in the Licensed Field. In addition, Licensor hereby grants to Licensee a worldwide nonexclusive right and license to use Licensors Materials and Information to the extent and only to the extent necessary to develop and commercialize Licensed Products in the Licensed Field.
License Property
Licensed Product shall mean any product that contains a Properdin Antibody, or any service that utilizes a Properdin Antibody.

Licensor Patent Rights shall mean, collectively, (a) all patents and patent applications listed and any foreign counterparts claiming priority therefrom; (b) all patent applications heretofore or hereafter filed in any country which claim (and only to the extent they claim) the Licensor Materials and Information or the use thereof; (c) all patents that have issued or in the future issue from any of the foregoing patent applications, including without limitation utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part,reissues, reexamination certificates or renewals from, extensions of or additions to any such patents or patent applications. Notwithstanding the foregoing, Licensor Patent Rights shall not include any Patent Rights that are within the Licensee Patent Rights, the Joint Patent Rights or the Properdin Antibody Patent Rights.

Patent Application Pending: US 09/138,723

Licensor Know-How shall mean all Know-How developed or acquired by Licensor solely or jointly with a Third Party that is related to Properdin Antibodies.

Joint Patent Rights shall mean all Patent Rights that claim Joint Inventions.

Joint Know-How shall mean Know-How developed or acquired jointly by employees or agents of both Licensor and Licensee as a result of their collaboration under the 1999 Agreement or under this Agreement; provided that such Know-How does not include subject matter within the Licensee Materials and Information, the Licensor Materials and Information or the Properdin Antibody Materials and Information.

Licensor Materials and Information shall mean, collectively, (a) the Antigen; (b) all reagents, samples and other chemical or biological materials regarding the Antigen which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen under this Agreement; and (c) all information (and all tangible and intangible embodiments thereof) regarding the foregoing, irrespective of inventorship, which is disclosed by Licensor to Licensee hereunder or which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen pursuant to this Agreement. Notwithstanding the foregoing, Licensor Materials and Information shall not include subject matter within the Licensee Materials and Information or the Properdin Antibody Materials and Information.

Field of Use
Acquiring right relates to the development and commercialization of anti-properdin antibody therapies.  An anti-properdin antibody may be a potential treatment for cardiovascular or inflammatory disease.

IPSCIO Record ID: 4690

License Grant
The Licensee agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology.
License Property
The non-exclusive license is to a worldwide portfolio of patents and patent applications directed to Diagnosis and Prognosis of Breast Cancer Patients (e.g., claiming priority to U.S. Provisional Patent Nos. 60/298918 and/or 60/380710) in the fields of research, diagnosis, prognosis and/or prediction of therapeutic outcome or risk for humans or animals in the area of oncology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.